FOLFOXIRI Bests FOLFIRI When Bevacizumab is Added in Colorectal Cancer

SAN FRANCISCO (IMNG) - Adding bevacizumab to the FOLFOXIRI regimen significantly delayed the median time to progression of metastatic colorectal cancer to 12.2 months, compared with 9.7 months when bevacizumab...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news